<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01589640</url>
  </required_header>
  <id_info>
    <org_study_id>EDD-BLNK-12-001</org_study_id>
    <nct_id>NCT01589640</nct_id>
  </id_info>
  <brief_title>Patient Satisfaction and Tear Osmolarity With the Use of Blink Tears, Blink Gel Tears and Systane Balance</brief_title>
  <official_title>Phase 4 Study Accessing Patient Satisfaction and Tear Osmolarity While Using Blink Tears, Blink Gel Tears and Systane Balance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ophthalmic Consultants of Connecticut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ophthalmic Consultants of Connecticut</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center clinical study designed to determine patient satisfaction and the
      effect of the use of artificial tears on tear osmolarity with time after instillation of
      three commercially available artifical tear eye solutions ( Blink Tears, Blink Gel Tears and
      Systane Balance).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient satisfaction and tear osmolarity with the use of Blink Tears, Blink Gel Tears and
      Systane Balance.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy variable is tear osmolarity</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy variable is the Patient Symptom Questionnaire</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Blink Tears</arm_group_label>
    <description>Blink Tears is an over the counter artificial tear</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blink Gel Tears</arm_group_label>
    <description>Blink Gel Tears is an over the counter artifical tear product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systane Balance</arm_group_label>
    <description>Systane Balance is an over the counter artificial Tear product</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blink Tears lubricating Eye Drops</intervention_name>
    <description>2 drops per eye drosed four times per day (8:00 Am, 12:00 PM, 4:00 PM and 8:00 PM)</description>
    <arm_group_label>Blink Tears</arm_group_label>
    <other_name>Blink Tears</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blink Gel Tears Lubricating Eye Drops</intervention_name>
    <description>2 drops per eye dosed four times per day (8:00 AM, 12:00PM, 4:00 PM and 8:00 PM)</description>
    <arm_group_label>Blink Gel Tears</arm_group_label>
    <other_name>Blink Gel Tears</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Systane Balance Lubricant Eye Drop</intervention_name>
    <description>2 Drops per eye dosed four times per day ( 8:00 AM, 12:00 PM, 4:00 PM and 8:00PM)</description>
    <arm_group_label>Systane Balance</arm_group_label>
    <other_name>Systane Balance</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        greater then age 18
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or femal subjects (aged 18 or older)

          -  diagnosed with mild to moderate dry eye syndrome

          -  provide written informed consent and sign/date a health information release

          -  women of childbreaing potential must be willing to practice effective contraception
             for the duration of the study.

        Exclusion Criteria:

          -  have any active ocular disease other than mild to moderate dry eye sundrome that would
             interfere with study interpretation

          -  active ocular allergy in any eye

          -  history of or active ocular infection/inflammation

          -  concomitant use of contact lenses (unilateral or bilateral)

          -  history of any corneal refractive laser surgery (e.g., LASIK, LASEK, RK,PRK) in the
             study eye (s);

          -  corneal disorder or abnormality that affects cornea sensitivity or normal spreading of
             the tear film in any eye.

          -  history of any intaocular surgery or glaucoma laser surgery (e.g., ALT, SLT) in the
             study eye (s)

          -  known sensitivity or allergy to any of the study medications or their components;

          -  uncontrolled systemic disease;

          -  contraindication to pupil dilation;

          -  Schirmer's Test- Standard Test (with anesthesia) result of less than or equal to 3 MM

          -  use of artifical tears prior to Baseline Visit (Visit 2, Day 0);

          -  Current use, use within 2 weeks prior to Baseline Visit ( Visit 2,Day 0) or likely use
             during the study period of any topical ophthalmic medications (e.g., antibotics,
             glaucoma medications) other than ophthalmic medications used in the study.

          -  use of any omega 3 supplement, artificial tear product (s), vasoconstrictor and/or
             redness reliever ocular drops 30 days prior to or during the study perior;

          -  use of cyclosporine ocular drops 12 months prior to or will require ocular surgery
             during the study period.

          -  females who are pregnany, nursing or planning a pregnancy or who are of childbearing
             potenital and not using a reliable method of contraception;

          -  any systemic disease or clinical evidence of any condition which would make the
             subject, in the opinion of the investigator, unsuitable for the study or could
             potentially confound the study results; and

          -  concurrent participation or prior participation in any investigational drug or device
             study within the last 30 days prior to the Screening Visit (Visit 1)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Donnenfeld, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Consultants of Connecticut</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>eric D Donnenfeld, M.D.</last_name>
    <phone>203-366-8000</phone>
    <email>eddoph@aol.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>denise lavin</last_name>
    <phone>203-366-8000</phone>
    <email>dlavin@occeye.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Connecticut</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2012</study_first_submitted>
  <study_first_submitted_qc>May 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2012</study_first_posted>
  <last_update_submitted>May 1, 2012</last_update_submitted>
  <last_update_submitted_qc>May 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

